Comparison of an oncology clinical decision-support system’s recommendations with actual treatment decisions
| Autor: | Metasebya Solomon, Gretchen Purcell Jackson, Yull E. Arriaga, Surasit Issarachai, Palita Lungchukiet, Rezzan Hekmat, Irene Dankwa-Mullan, Edward H. Shortliffe, Tanawat Jirakulaporn, Pattanawadee Wongrattananon, Nimit Taechakraichana, Wisanu Boonpakdee, Wimolrat Decha, Harit Suwanrusme, Suthida Suwanvecho, Vimla L. Patel, Anita M. Preininger, Narongsak Kiatikajornthada, Nittaya Thanakarn, Suwei Wang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
concordance
Oncology medicine.medical_specialty AcademicSubjects/SCI01060 Colorectal cancer Concordance Clinical Decision-Making Health Informatics Research and Applications Medical Oncology Clinical decision support system clinical decision-support systems breast cancer Breast cancer Artificial Intelligence Neoplasms Internal medicine medicine Humans Stage (cooking) rectal cancer Lung cancer AcademicSubjects/MED00580 Neoplasm Staging Descriptive statistics business.industry Decision Support Systems Clinical Thailand medicine.disease lung cancer colon cancer Therapy Computer-Assisted Treatment decision making AcademicSubjects/SCI01530 Watson for Oncology business |
| Zdroj: | Journal of the American Medical Informatics Association : JAMIA |
| ISSN: | 1527-974X |
| DOI: | 10.1093/jamia/ocaa334 |
| Popis: | Objective IBM(R) Watson for Oncology (WfO) is a clinical decision-support system (CDSS) that provides evidence-informed therapeutic options to cancer-treating clinicians. A panel of experienced oncologists compared CDSS treatment options to treatment decisions made by clinicians to characterize the quality of CDSS therapeutic options and decisions made in practice. Methods This study included patients treated between 1/2017 and 7/2018 for breast, colon, lung, and rectal cancers at Bumrungrad International Hospital (BIH), Thailand. Treatments selected by clinicians were paired with therapeutic options presented by the CDSS and coded to mask the origin of options presented. The panel rated the acceptability of each treatment in the pair by consensus, with acceptability defined as compliant with BIH’s institutional practices. Descriptive statistics characterized the study population and treatment-decision evaluations by cancer type and stage. Results Nearly 60% (187) of 313 treatment pairs for breast, lung, colon, and rectal cancers were identical or equally acceptable, with 70% (219) of WfO therapeutic options identical to, or acceptable alternatives to, BIH therapy. In 30% of cases (94), 1 or both treatment options were rated as unacceptable. Of 32 cases where both WfO and BIH options were acceptable, WfO was preferred in 18 cases and BIH in 14 cases. Colorectal cancers exhibited the highest proportion of identical or equally acceptable treatments; stage IV cancers demonstrated the lowest. Conclusion This study demonstrates that a system designed in the US to support, rather than replace, cancer-treating clinicians provides therapeutic options which are generally consistent with recommendations from oncologists outside the US. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|